Apellis Pharmaceuticals Price Target Cut to $86.00/Share From $100.00 by Baird
Apellis Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $46
Apellis Pharmaceuticals Analyst Ratings
Baird Initiates Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $100
Apellis Pharmaceuticals Strengthened Market Position and Buy Rating Following Competitor's Clinical Failure
Stifel Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $84
Apellis Pharmaceuticals (APLS) Receives a Buy From Stifel Nicolaus
Analysts' Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Buy Rating Affirmed on Apellis Pharmaceuticals Amid Promising Pegcetacoplan Trials and Expert Optimism
Jefferies Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH) and Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Analyst Ratings
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $40 From $50, Maintains Neutral Rating
Apellis Pharmaceuticals Analyst Ratings
Apellis Pharmaceuticals Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)
Apellis Pharmaceuticals Analyst Ratings